The change was made to the polyethylene glycol 4000 source (manufacturer): after the clinical trial and in the process of preparing to apply for NDA, the decision was made in October 2018 to change its source from Hunan Erkang Pharmaceutical Co., Ltd. to Nanjing Weill Pharmaceutical Co., Ltd. according to the registration of polyethylene glycol 4000, the related review and risk assessment, and the corresponding research was carried out Support the change.
正在翻译中..